Published 1 month ago

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

Summary by Ground News

SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid and plasma Tau proteins in Alzheimer's patients. SNK01 given via a simple IV appears to cross the blood brain barrier to improve A�42/40, Tau, and alpha-synuclein protein levels in CSF. The primary endpoint was safety and secondary endpoints included changes in cognitive assessments and biomarker levels.

0 Articles

All

Left

Center

Right

Globe Newswire

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients. The...

1 month ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated1 month agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

0 Articles

0 Articles

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics